Generic Name and Formulations:
Alprazolam 0.25mg, 0.5mg, 1mg, 2mg+; scored tabs (+multi-scored).
Indications for XANAX:
Anxiety. Panic disorder.
Adjust at intervals of at least 3–4 days. ≥18yrs: Anxiety: initially 0.25–0.5mg 3 times daily; max 4mg daily in divided doses. Elderly or debilitated: initially 0.25mg 2–3 times daily. Panic disorder: initially 0.5mg 3 times daily; usual range: 5–6mg daily in divided doses; max 10mg/day.
<18yrs: not established.
Concomitant itraconazole, ketoconazole.
Risks from concomitant use with opioids; see Interactions. Suicidal ideation. Depression. Psychosis. Mania. Renal, cardiovascular, hepatic, or pulmonary impairment; monitor. Obesity. Reevaluate periodically. Change dose gradually. Withdrawal symptoms on abrupt cessation or dose reduction. Monitor periodic CBCs, urinalysis, blood chemistry. Drug or alcohol abuse. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.D), nursing mothers: not recommended.
See Contraindications; other azole antifungals: not recommended. Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants (eg, other benzodiazepines, psychotropics, anticonvulsants, antihistamines); consider dose reductions. Potentiated by CYP3A inhibitors (eg, cimetidine, nefazodone, fluvoxamine); reduce alprazolam dose; caution with weaker CYP3A inhibitors (eg, fluoxetine, propoxyphene, oral contraceptives). Caution with diltiazem, isoniazid, erythromycin, clarithromycin, grapefruit juice, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, nifedipine, others metabolized by CYP3A. Antagonized by CYP3A inducers (eg, carbamazepine). May increase levels of imipramine, desipramine.
CNS depression (eg, sedation, somnolence, memory impairment, dysarthria, coordination abnormal, ataxia), fatigue, lethargy, dyspnea, dry mouth, constipation, withdrawal seizures, tremors, decreased libido, sexual dysfunction, paradoxical excitement.
XR—60; Tabs 0.25mg, 0.5mg, 1mg—100, 500, 1000; 2mg—100, 500
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|